Related references
Note: Only part of the references are listed.CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer
Jonathan H. Shepherd et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Treatment landscape of triple-negative breast cancer - expanded options, evolving needs
Giampaolo Bianchini et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2022)
Platinum-based drugs for cancer therapy and anti-tumor strategies
Chunyu Zhang et al.
THERANOSTICS (2022)
Exosomal microRNAs synergistically trigger stromal fibroblasts in breast cancer
Iolanda Scognamiglio et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2022)
PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors
Anna D. Staniszewska et al.
ONCOIMMUNOLOGY (2022)
FDA Approval Summary: Tucatinib for the Treatment of Patients with Advanced or Metastatic HER2-positive Breast Cancer
Mirat Shah et al.
CLINICAL CANCER RESEARCH (2021)
Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials
Matthew P. Goetz et al.
BREAST CANCER RESEARCH AND TREATMENT (2021)
Adjuvant CDK4/6 inhibitors combined with endocrine therapy in HR-positive, HER2-negative early breast cancer: A meta-analysis of randomized clinical trials
Hong-Fei Gao et al.
BREAST (2021)
Combining histone deacetylase inhibitors (HDACis) with other therapies for cancer therapy
Mengjiao Zhou et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2enegative advanced breast cancer: final overall survival results from SOLAR-1
F. Andre et al.
ANNALS OF ONCOLOGY (2021)
Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study
Leisha A. Emens et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)
Case Report: Long-Term Response to Pembrolizumab Combined With Endocrine Therapy in Metastatic Breast Cancer Patients With Hormone Receptor Expression
Dingyong Wu et al.
FRONTIERS IN IMMUNOLOGY (2021)
Tioconazole and Chloroquine Act Synergistically to Combat Doxorubicin-Induced Toxicity via Inactivation of PI3K/AKT/mTOR Signaling Mediated ROS-Dependent Apoptosis and Autophagic Flux Inhibition in MCF-7 Breast Cancer Cells
Afnan H. El-Gowily et al.
PHARMACEUTICALS (2021)
Trastuzumab emtansine (T-DM1) versus trastuzumab in Chinese patients with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy for HER2-positive breast cancer in the phase 3 KATHERINE study
Chiun-Sheng Huang et al.
BREAST CANCER RESEARCH AND TREATMENT (2021)
The Use of Nanomedicine to Target Signaling by the PAK Kinases for Disease Treatment
Yiling Wang et al.
CELLS (2021)
Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial
Sibylle Loibl et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Breast cancer
Sibylle Loibl et al.
LANCET (2021)
piR-39980 mediates doxorubicin resistance in fibrosarcoma by regulating drug accumulation and DNA repair
Basudeb Das et al.
COMMUNICATIONS BIOLOGY (2021)
AKT Inhibitors: New Weapons in the Fight Against Breast Cancer?
Federica Martorana et al.
FRONTIERS IN PHARMACOLOGY (2021)
The EMA review of trastuzumab emtansine (T-DM1) for the adjuvant treatment of adult patients with HER2-positive early breast cancer
J. Delgado et al.
ESMO OPEN (2021)
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival
D. J. Slamon et al.
ANNALS OF ONCOLOGY (2021)
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
D. Miles et al.
ANNALS OF ONCOLOGY (2021)
Relevance of Aromatase Inhibitors in Breast Cancer Treatment
Ankita Sood et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2021)
Efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors as second-line treatment in postmenopausal patients with hormone receptor-positive, HER-2-negative metastatic breast cancer: a network meta-analysis
John Hang Leung et al.
EXPERT OPINION ON DRUG SAFETY (2021)
Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update
Harold J. Burstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
Jinhua Liu et al.
FRONTIERS IN PHARMACOLOGY (2021)
Systematic review of combinations of targeted or immunotherapy in advanced solid tumors
Aaron C. Tan et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Unraveling Immune-Related lncRNAs in Breast Cancer Molecular Subtypes
Carolina Mathias et al.
FRONTIERS IN ONCOLOGY (2021)
Metastatic heterogeneity of breast cancer: Molecular mechanism and potential therapeutic targets
Yiran Liang et al.
SEMINARS IN CANCER BIOLOGY (2020)
Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study
P. Schmid et al.
ANNALS OF ONCOLOGY (2020)
Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis
Laura M. Spring et al.
CLINICAL CANCER RESEARCH (2020)
Landscape of combination therapy trials in breast cancer brain metastasis
Jawad Fares et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
A new immunotherapy schedule in addition to first-line hormone therapy for metastatic breast cancer patients in a state of clinical benefit during hormone therapy
Andrea Nicolini et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2020)
CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis
Jennifer J. Gao et al.
LANCET ONCOLOGY (2020)
Pembrolizumab for Early Triple-Negative Breast Cancer
Peter Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
R. K. Murthy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Precision Medicine and Targeted Therapies in Breast Cancer
Ian Greenwalt et al.
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA (2020)
Aromatase inhibitors: Role in postmenopausal breast cancer
Rajeev Kharb et al.
ARCHIV DER PHARMAZIE (2020)
Progesterone Receptor Gene Variants in Metastatic Estrogen Receptor Positive Breast Cancer
Amy M. Fowler et al.
HORMONES & CANCER (2020)
Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer
Anniina Farkkila et al.
NATURE COMMUNICATIONS (2020)
Small molecules, big impact: 20 years of targeted therapy in oncology
Philippe L Bedard et al.
LANCET (2020)
ALDH1+stem cells demonstrate more stem cell-like characteristics than CD44+/CD24-/low stem cells in different molecular subtypes of breast cancer
Jie Chen et al.
TRANSLATIONAL CANCER RESEARCH (2020)
Enhanced oral bioavailability and bioefficacy of phloretin using mixed polymeric modified self-nanoemulsions
Yiling Wang et al.
FOOD SCIENCE & NUTRITION (2020)
In SilicoScreening of Potential Chinese Herbal Medicine Against COVID-19 by Targeting SARS-CoV-2 3CLpro and Angiotensin Converting Enzyme II Using Molecular Docking
Liang-qin Gao et al.
CHINESE JOURNAL OF INTEGRATIVE MEDICINE (2020)
A Bioinformatics Research on Novel Mechanism of Compound Kushen Injection for Treating Breast Cancer by Network Pharmacology and Molecular Docking Verification
Shuyu Liu et al.
EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE (2020)
ICON: a randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer
J. A. Kyte et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2020)
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study
Susan M. Domchek et al.
LANCET ONCOLOGY (2020)
Molecular and Cellular Factors Associated with Racial Disparity in Breast Cancer
Manish Charan et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Targeting Autophagy in Breast Cancer
Stefania Cocco et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
Stephen R. D. Johnston et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
Elizabeth A. Mittendorf et al.
LANCET (2020)
Clinical failure of nanoparticles in cancer: mimicking nature's solutions
Pablo Hernandez-Camarero et al.
NANOMEDICINE (2020)
Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives
Jin-Yu Sun et al.
BIOMARKER RESEARCH (2020)
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
Javier Cortes et al.
LANCET (2020)
Investigating the EPR effect of nanomedicines in human renal tumors via ex vivo perfusion strategy
Yuxun Ding et al.
NANO TODAY (2020)
Empagliflozin and Doxorubicin Synergistically Inhibit the Survival of Triple-Negative Breast Cancer Cells via Interfering with the mTOR Pathway and Inhibition of Calmodulin: In Vitro and Molecular Docking Studies
Shenouda G. Eliaa et al.
ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE (2020)
A comprehensive overview of metaplastic breast cancer: clinical features and molecular aberrations
Tejaswini P. Reddy et al.
BREAST CANCER RESEARCH (2020)
Triple negative breast cancer: special histological types and emerging therapeutic methods
Lu Cao et al.
CANCER BIOLOGY & MEDICINE (2020)
Dual or multiple drug loaded nanoparticles to target breast cancer stem cells
Yu Gao et al.
RSC ADVANCES (2020)
Cell deformation and acquired drug resistance: elucidating the major influence of drug-nanocarrier delivery systems
Semonti Nandi et al.
JOURNAL OF MATERIALS CHEMISTRY B (2020)
Targeting cancer stem cell pathways for cancer therapy
Liqun Yang et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)
Breast cancer stem cells: Biology and therapeutic implications
Ramesh Butti et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2019)
Metformin and Breast Cancer: Molecular Targets
J. Faria et al.
JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA (2019)
Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment
Ana C. Garrido-Castro et al.
CANCER DISCOVERY (2019)
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer
Fabrice Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Stem Cells Inhibition by Bevacizumab in Combination with Neoadjuvant Chemotherapy for Breast Cancer
Renaud Sabatier et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer
Shaveta Vinayak et al.
JAMA ONCOLOGY (2019)
Are 90% of deaths from cancer caused by metastases?
Hanna Dillekas et al.
CANCER MEDICINE (2019)
Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer-How We Can Rise to the Challenge
Milica Nedeljkovic et al.
CELLS (2019)
Antiestrogens in combination with immune checkpoint inhibitors in breast cancer immunotherapy
Diana C. Marquez-Garban et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2019)
A Network Pharmacology-Based Strategy For Predicting Active Ingredients And Potential Targets Of LiuWei DiHuang Pill In Treating Type 2 Diabetes Mellitus
Dan He et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2019)
Cocktail Strategy Based on Spatio-Temporally Controlled Nano Device Improves Therapy of Breast Cancer
Tianqun Lang et al.
ADVANCED MATERIALS (2019)
Cabazitaxel and thymoquinone co-loaded lipospheres as a synergistic combination for breast cancer
Nagavendra Kommineni et al.
CHEMISTRY AND PHYSICS OF LIPIDS (2019)
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
G. von Minckwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
AMP-activated protein kinase: a potential therapeutic target for triple-negative breast cancer
Wei Cao et al.
BREAST CANCER RESEARCH (2019)
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer
Stephen Johnston et al.
NPJ BREAST CANCER (2019)
Emerging blood-brain-barrier-crossing nanotechnology for brain cancer theranostics
Wei Tang et al.
CHEMICAL SOCIETY REVIEWS (2019)
Taxanes for adjuvant treatment of early breast cancer
Melina L. Willson et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2019)
The Multi-Functional Calcium/Calmodulin Stimulated Protein Kinase (CaMK) Family: Emerging Targets for Anti-Cancer Therapeutic Intervention
Joshua S. Brzozowski et al.
PHARMACEUTICALS (2019)
A preliminary study on treatment of human breast cancer xenografts with a cocktail of paclitaxel, doxorubicin, and 131I-anti-epithelial cell adhesion molecule (9C4)
Naiim S. Ali et al.
WORLD JOURNAL OF NUCLEAR MEDICINE (2019)
Cancer stem cells in triple-negative breast cancer: a potential target and prognostic marker
Christopher J. O'Conor et al.
BIOMARKERS IN MEDICINE (2018)
Everolimus Plus Letrozole for Treatment of Patients With HR+, HER2- Advanced Breast Cancer Progressing on Endocrine Therapy: An Open-label, Phase II Trial
Tamar Safra et al.
CLINICAL BREAST CANCER (2018)
The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells
Daniele Cretella et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2018)
Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment
Hitisha K. Patel et al.
PHARMACOLOGY & THERAPEUTICS (2018)
Combination Therapies Targeting HDAC and IKK in Solid Tumors
Ivana Vancurova et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2018)
Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer A Clinical Trial
Melanie Royce et al.
JAMA ONCOLOGY (2018)
Combinations of Bevacizumab With Cancer Immunotherapy
Daniel S. Chen et al.
CANCER JOURNAL (2018)
First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial
Mothaffar Rimawi et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer
Kathryn C. Arbour et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Adjuvant Anthracyclines in Breast Cancer: What Is Their Role?
Ami N. Shah et al.
ONCOLOGIST (2018)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Precision medicine in breast cancer
Yoichi Naito et al.
CHINESE CLINICAL ONCOLOGY (2018)
Breast Cancer Immunotherapy: Facts and Hopes
Leisha A. Emens
CLINICAL CANCER RESEARCH (2018)
Nanoparticles and targeted drug delivery in cancer therapy
Behdokht Bahrami et al.
IMMUNOLOGY LETTERS (2017)
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Matthew P. Goetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Extraction, bioavailability, and bioefficacy of capsaicinoids
Muwen Lu et al.
JOURNAL OF FOOD AND DRUG ANALYSIS (2017)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark Robson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Molecular classification of breast cancer: what the pathologist needs to know
Emad A. Rakha et al.
PATHOLOGY (2017)
Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab
Reva K. Basho et al.
JAMA ONCOLOGY (2017)
Breast Cancer: Current Molecular Therapeutic Targets and New Players
Siddavaram Nagini
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2017)
Breast Cancer Molecular Stratification From Intrinsic Subtypes to Integrative Clusters
Hege G. Russnes et al.
AMERICAN JOURNAL OF PATHOLOGY (2017)
Landscape of Combination Immunotherapy and Targeted Therapy to Improve Cancer Management
Leandro M. Colli et al.
CANCER RESEARCH (2017)
Trastuzumab in the Treatment of Breast Cancer
Sofia Maximiano et al.
BIODRUGS (2016)
A pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancer
Bang-Bin Chen et al.
BMC CANCER (2016)
Immunotherapy and Hormone-therapy in Metastatic Breast Cancer: A Review and an Update
Andrea Nicolini et al.
CURRENT DRUG TARGETS (2016)
Treatment strategies for advanced hormone receptor-positive and human epidermal growth factor 2-negative breast cancer: the role of treatment order
Edith A. Perez
DRUG RESISTANCE UPDATES (2016)
Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial
Ian E. Krop et al.
LANCET ONCOLOGY (2016)
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
Douglas B. dbj Johnson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Anti-Breast Cancer Potential of Quercetin via the Akt/AMPK/Mammalian Target of Rapamycin (mTOR) Signaling Cascade
Amilcar Rivera Rivera et al.
PLOS ONE (2016)
Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor
Kimberly Blackwell et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
Managing Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer Who Progress on Endocrine Therapies with Inhibitors of the PI3K Pathway
Adam M. Brufsky
BREAST JOURNAL (2014)
Use of SERMs for treatment in postmenopausal women
Joann V. Pinkerton et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2014)
Molecular classification of breast cancer
Darina Vuong et al.
VIRCHOWS ARCHIV (2014)
Targeting PI3K/Akt/mTOR signaling in cancer
Camillo Porta et al.
FRONTIERS IN ONCOLOGY (2014)
Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase
Xiaoyong Fu et al.
BREAST CANCER RESEARCH (2014)
Biological subtypes of breast cancer: Prognostic and therapeutic implications
Ozlem Yersal et al.
WORLD JOURNAL OF CLINICAL ONCOLOGY (2014)
Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives
A. Milani et al.
ANNALS OF ONCOLOGY (2013)
Preclinical and Clinical Studies of Gamma Secretase Inhibitors with Docetaxel on Human Breast Tumors
Anne F. Schott et al.
CLINICAL CANCER RESEARCH (2013)
Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors
Jacqueline D. Peacock et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
Comparison of basal-like triple-negative breast cancer defined by morphology, immunohistochemistry and transcriptional profiles
Patrycja Gazinska et al.
MODERN PATHOLOGY (2013)
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
Christina Davies et al.
LANCET (2013)
The Discovery and Development of Selective Estrogen Receptor Modulators (SERMs) for Clinical Practice
Philipp Y. Maximov et al.
CURRENT CLINICAL PHARMACOLOGY (2013)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
The cost of drug development: A systematic review
Steve Morgan et al.
HEALTH POLICY (2011)
Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists
Sunil Badve et al.
MODERN PATHOLOGY (2011)
Downregulation of CD44 reduces doxorubicin resistance of CD44(+)CD24(-) breast cancer cells
Pham Van Phuc et al.
ONCOTARGETS AND THERAPY (2011)
The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses
Lucy S. K. Walker et al.
NATURE REVIEWS IMMUNOLOGY (2011)
Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells
Robert H. Vonderheide et al.
CLINICAL CANCER RESEARCH (2010)
Correlation between NK function and response to trastuzumab in metastatic breast cancer patients
Alessandra Beano et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2008)
Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2
Stefania Varchetta et al.
CANCER RESEARCH (2007)
Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?
L Arnould et al.
BRITISH JOURNAL OF CANCER (2006)
Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies
Ting-Chao Chou
PHARMACOLOGICAL REVIEWS (2006)
Beta-interferon and interleukin-2 prolong more than three times the survival of 26 consecutive endocrine dependent breast cancer patients with distant metastases: an exploratory trial
A Nicolini et al.
BIOMEDICINE & PHARMACOTHERAPY (2005)
Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women:: Analysis of survival and update of efficacy from the international letrozole breast cancer group
H Mouridsen et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
T Sorlie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Molecular portraits of human breast tumours
CM Perou et al.
NATURE (2000)
Share Paper
